| P2093 | author name string | R A Hill | |
| | S Alqahtani | |
| | A Kaddoumi | |
| | L A Mohamed | |
| | B S Abuasal | |
| | H Qosa | |
| P2860 | cites work | ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models | Q24628845 |
| | ApoE promotes the proteolytic degradation of Abeta | Q24651102 |
| | Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? | Q27690256 |
| | Pathobiology of ischaemic stroke: an integrated view | Q28141682 |
| | Differential regulation of transport proteins in the periinfarct region following reversible middle cerebral artery occlusion in rats | Q28577969 |
| | Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders | Q29615839 |
| | Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate | Q29620128 |
| | beta-Amyloid efflux mediated by p-glycoprotein | Q31962046 |
| | Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis | Q33742729 |
| | Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease | Q33862071 |
| | Drug resistance in brain diseases and the role of drug efflux transporters. | Q33988704 |
| | MDR1 gene expression in brain of patients with medically intractable epilepsy | Q34059935 |
| | Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling | Q34147024 |
| | Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice | Q34212267 |
| | Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. | Q34382218 |
| | Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease | Q34468561 |
| | OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users | Q34534509 |
| | Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging | Q34760415 |
| | Inhibiting drug efflux transporters improves efficacy of ALS therapeutics | Q34824777 |
| | Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis | Q34936454 |
| | Beta-Amyloid Downregulates MDR1-P-Glycoprotein (Abcb1) Expression at the Blood-Brain Barrier in Mice | Q35030142 |
| | ABCG2 variant has opposing effects on onset ages of Parkinson's disease and gout | Q35204897 |
| | Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up | Q35720625 |
| | Monocarboxylate transporter 1 is deficient on microvessels in the human epileptogenic hippocampus | Q35901040 |
| | PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease | Q35940134 |
| | Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS. | Q36007494 |
| | Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases | Q36191368 |
| | Oleocanthal enhances amyloid-β clearance from the brains of TgSwDI mice and in vitro across a human blood-brain barrier model | Q36301505 |
| | Establishment and Dysfunction of the Blood-Brain Barrier | Q36306827 |
| | Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease | Q36330297 |
| | Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders | Q36378047 |
| | Aβ40 Reduces P-Glycoprotein at the Blood-Brain Barrier through the Ubiquitin-Proteasome Pathway. | Q36564557 |
| | Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer's disease mouse model | Q36678091 |
| | The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects | Q36697929 |
| | ABCA7 Deficiency Accelerates Amyloid-β Generation and Alzheimer's Neuronal Pathology | Q36741016 |
| | Genetic variability in ABCB1, occupational pesticide exposure, and Parkinson's disease | Q37014527 |
| | ABCA7 expression is associated with Alzheimer's disease polymorphism and disease status | Q37394169 |
| | RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation? | Q37455857 |
| | Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease | Q37515497 |
| | Human transporter database: comprehensive knowledge and discovery tools in the human transporter genes | Q37591678 |
| | Age-Related Decline in Brain and Hepatic Clearance of Amyloid-Beta is Rectified by the Cholinesterase Inhibitors Donepezil and Rivastigmine in Rats | Q37596042 |
| | Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions | Q37617339 |
| | Targeting regulation of ABC efflux transporters in brain diseases: a novel therapeutic approach. | Q37629066 |
| | Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease | Q37949572 |
| | Cerebral expression of drug transporters in epilepsy | Q37964362 |
| | ATP-binding cassette transporter A1: from metabolism to neurodegeneration | Q38213077 |
| | Translating biological findings into new treatment strategies for amyotrophic lateral sclerosis (ALS). | Q38228849 |
| | Functional expression of drug transporters in glial cells: potential role on drug delivery to the CNS. | Q38259302 |
| | Intractable epilepsy and the P-glycoprotein hypothesis | Q38497941 |
| | Complete Knockout of Endogenous Mdr1 (Abcb1) in MDCK Cells by CRISPR-Cas9. | Q38794805 |
| | Addition of NMDA-receptor antagonist MK801 during oxygen/glucose deprivation moderately attenuates the upregulation of glucose uptake after subsequent reoxygenation in brain endothelial cells. | Q39450239 |
| | P-glycoprotein and breast cancer resistance protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid-beta | Q39860990 |
| | Adenosine triphosphate-binding cassette transporters mediate chemokine (C-C motif) ligand 2 secretion from reactive astrocytes: relevance to multiple sclerosis pathogenesis | Q42684230 |
| | ABC efflux transporters in brain vasculature of Alzheimer's subjects | Q42930763 |
| | Reduction of L-type amino acid transporter 1 mRNA expression in brain capillaries in a mouse model of Parkinson's disease | Q42981636 |
| | In vitro investigation of amyloid-β hepatobiliary disposition in sandwich-cultured primary rat hepatocytes | Q44053132 |
| | Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy | Q45029801 |
| | Monocarboxylate transporter expression in the spontaneous hypertensive rat: effect of stroke | Q45172743 |
| | Blood-brain barrier dysfunction in parkinsonian midbrain in vivo | Q45237161 |
| | T lymphocytes impair P-glycoprotein function during neuroinflammation. | Q45926037 |
| | ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. | Q45928375 |
| | Expression of multidrug transporters MRP1, MRP2, and BCRP shortly after status epilepticus, during the latent period, and in chronic epileptic rats | Q46725859 |
| | Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease | Q46738145 |
| | Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling | Q46840766 |
| | Neuronal mdr-1 gene expression after experimental focal hypoxia: a new obstacle for neuroprotection? | Q48188615 |
| | Receptor-associated protein promotes t-PA expression, reduces PAI-1 expression and improves neurorecovery after acute ischemic stroke. | Q48317624 |
| | Abcg2 deficiency augments oxidative stress and cognitive deficits in Tg-SwDI transgenic mice. | Q48518436 |
| | Interictal seizure resections show two configurations of endothelial Glut1 glucose transporter in the human blood-brain barrier. | Q48564420 |
| | Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia | Q48604379 |
| | Blood-brain barrier P-glycoprotein function in Alzheimer's disease. | Q50778486 |
| | Alteration in P-glycoprotein at the blood-brain barrier in the early period of MCAO in rats. | Q51060989 |
| | Dual pathways mediate β-amyloid stimulated glutathione release from astrocytes. | Q53478464 |
| | Parkinson's disease | Q54072241 |
| | RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease | Q95823643 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 441-453 | |
| P577 | publication date | 2016-07-22 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Transporters as Drug Targets in Neurological Diseases | |
| P478 | volume | 100 | |